Pharmacokinetics of prolonged-release tacrolimus and implications for use in solid organ transplant recipients

被引:24
作者
Tanzi, Maria G. [1 ]
Undre, Nasrullah [2 ]
Keirns, James [1 ]
Fitzsimmons, William E. [1 ]
Brown, Malcolm [3 ]
First, M. Roy [4 ]
机构
[1] Astellas Pharma Global Dev, Northbrook, IL USA
[2] Astellas Pharma Europe Ltd, Surrey, England
[3] Astellas Pharma Global Dev, Surrey, England
[4] Transplant Genom Inc, Brookline, MA USA
关键词
pharmacokinetics; tacrolimus prolonged-release; ONCE-DAILY TACROLIMUS; TWICE-DAILY TACROLIMUS; NOVO KIDNEY-TRANSPLANTATION; PROGRAF-BASED REGIMEN; 1-YEAR FOLLOW-UP; OPEN-LABEL TRIAL; PATIENT VARIABILITY; EXTENDED-RELEASE; CONVERSION; FORMULATIONS;
D O I
10.1111/ctr.12763
中图分类号
R61 [外科手术学];
学科分类号
摘要
Prolonged-release tacrolimus was developed as a once-daily formulation with ethylcellulose as the excipient, resulting in slower release and reduction in peak concentration (C-max) for a given dose compared with immediate-release tacrolimus, which is administered twice daily. This manuscript reviews pharmacokinetic information on prolonged-release tacrolimus in healthy subjects, in transplant recipients converted from immediate-release tacrolimus, and in de novo kidney and liver transplant recipients. As with the immediate-release formulation, prolonged-release tacrolimus shows a strong correlation between trough concentration (C-min) and area under the 24-hour time-concentration curve (AUC(24)), indicating that trough whole blood concentrations provide an accurate measure of drug exposure. We present the pharmacokinetic similarities and differences between the two formulations, so that prescribing physicians will have a better understanding of therapeutic drug monitoring in patients receiving prolonged-release tacrolimus.
引用
收藏
页码:901 / 911
页数:11
相关论文
共 38 条
[1]   Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen [J].
Alloway, R ;
Steinberg, S ;
Khalil, K ;
Gourishankar, S ;
Miller, J ;
Norman, D ;
Hariharan, S ;
Pirsch, J ;
Matas, A ;
Zaltzman, J ;
Wisemandle, K ;
Fitzsimmons, W ;
First, MR .
TRANSPLANTATION PROCEEDINGS, 2005, 37 (02) :867-870
[2]   Pharmacokinetics in stable head transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations [J].
Alloway, Rita ;
Vanhaecke, Johan ;
Yonan, Nizar ;
White, Michel ;
Haddad, Haissam ;
Rabago, Gregorio ;
Tymchak, Wayne ;
Molina, Beatriz Diaz ;
Grimm, Michael ;
Eiskjaer, Hans ;
Karpf, Carmen ;
Undre, Nasrullah .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (09) :1003-1010
[3]  
[Anonymous], 2005, ADHERENCE LONG TERM
[4]  
Astellas Pharma Europe Ltd, 2015, ADV SUMM PROD CHAR
[5]  
Astellas Pharma US Inc, 2013, AST XL PRESCR INF
[6]  
Astellas Pharma US Inc, 2013, PROGR PRESCR INF
[7]  
Astellas Pharma US Inc, AST XL DAT FIL
[8]   Once- Versus Twice-Daily Tacrolimus Are the Formulations Truly Equivalent? [J].
Barraclough, Katherine A. ;
Isbel, Nicole M. ;
Johnson, David W. ;
Campbell, Scott B. ;
Staatz, Christine E. .
DRUGS, 2011, 71 (12) :1561-1577
[9]   High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation [J].
Borra, Lennaert C. P. ;
Roodnat, Joke I. ;
Kal, Judith A. ;
Mathot, Ron A. A. ;
Weimar, Willem ;
van Gelder, Teun .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (08) :2757-2763
[10]   Conversion from Prograf to Advagraf in stable paediatric renal transplant patients and 1-year follow-up [J].
Carcas-Sansuan, Antonio J. ;
Espinosa-Roman, Laura ;
Almeida-Paulo, Gonzalo N. ;
Alonso-Melgar, Angel ;
Garcia-Meseguer, Carmen ;
Fernandez-Camblor, Carlota ;
Medrano, Nicolas ;
Ramirez, Elena .
PEDIATRIC NEPHROLOGY, 2014, 29 (01) :117-123